Finally, an important next step would be to relate changes on the new battery to biomarkers associated with the development of AD in DS, including fluid biomarkers such as neurofilament light, plasma, and neuroimaging measures of tau and amyloid.17, 32, 33. This evidence concerns the gene MAPT and Alzheimer disease.